272 related articles for article (PubMed ID: 27224921)
1. Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Gale M; Sayegh J; Cao J; Norcia M; Gareiss P; Hoyer D; Merkel JS; Yan Q
Oncotarget; 2016 Jun; 7(26):39931-39944. PubMed ID: 27224921
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of KDM5A for cancer treatment.
Yang GJ; Wu J; Miao L; Zhu MH; Zhou QJ; Lu XJ; Lu JF; Leung CH; Ma DL; Chen J
Eur J Med Chem; 2021 Dec; 226():113855. PubMed ID: 34555614
[TBL] [Abstract][Full Text] [Related]
3. Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy.
Yang GJ; Wang W; Mok SWF; Wu C; Law BYK; Miao XM; Wu KJ; Zhong HJ; Wong CY; Wong VKW; Ma DL; Leung CH
Angew Chem Int Ed Engl; 2018 Oct; 57(40):13091-13095. PubMed ID: 29968419
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of KDM5A in human cancer.
Yang GJ; Zhu MH; Lu XJ; Liu YJ; Lu JF; Leung CH; Ma DL; Chen J
J Hematol Oncol; 2021 Feb; 14(1):30. PubMed ID: 33596982
[TBL] [Abstract][Full Text] [Related]
5. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen.
Sayegh J; Cao J; Zou MR; Morales A; Blair LP; Norcia M; Hoyer D; Tackett AJ; Merkel JS; Yan Q
J Biol Chem; 2013 Mar; 288(13):9408-17. PubMed ID: 23408432
[TBL] [Abstract][Full Text] [Related]
6. The KDM5 family of histone demethylases as targets in oncology drug discovery.
Rasmussen PB; Staller P
Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
8. The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
Oser MG; Sabet AH; Gao W; Chakraborty AA; Schinzel AC; Jennings RB; Fonseca R; Bonal DM; Booker MA; Flaifel A; Novak JS; Christensen CL; Zhang H; Herbert ZT; Tolstorukov MY; Buss EJ; Wong KK; Bronson RT; Nguyen QD; Signoretti S; Kaelin WG
Genes Dev; 2019 Dec; 33(23-24):1718-1738. PubMed ID: 31727771
[TBL] [Abstract][Full Text] [Related]
9. KDM5 lysine demethylases are involved in maintenance of 3'UTR length.
Blair LP; Liu Z; Labitigan RL; Wu L; Zheng D; Xia Z; Pearson EL; Nazeer FI; Cao J; Lang SM; Rines RJ; Mackintosh SG; Moore CL; Li W; Tian B; Tackett AJ; Yan Q
Sci Adv; 2016 Nov; 2(11):e1501662. PubMed ID: 28138513
[TBL] [Abstract][Full Text] [Related]
10. Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A.
Petronikolou N; Longbotham JE; Fujimori DG
Biochemistry; 2020 Feb; 59(5):647-651. PubMed ID: 31985200
[TBL] [Abstract][Full Text] [Related]
11. Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Dai B; Huang H; Guan F; Zhu G; Xiao Z; Mao B; Su H; Hu Z
Biomed Pharmacother; 2018 Mar; 99():72-80. PubMed ID: 29324315
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
13. Depletion of Histone Demethylase Jarid1A Resulting in Histone Hyperacetylation and Radiation Sensitivity Does Not Affect DNA Double-Strand Break Repair.
Penterling C; Drexler GA; Böhland C; Stamp R; Wilke C; Braselmann H; Caldwell RB; Reindl J; Girst S; Greubel C; Siebenwirth C; Mansour WY; Borgmann K; Dollinger G; Unger K; Friedl AA
PLoS One; 2016; 11(6):e0156599. PubMed ID: 27253695
[TBL] [Abstract][Full Text] [Related]
14. Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer.
Hou J; Wu J; Dombkowski A; Zhang K; Holowatyj A; Boerner JL; Yang ZQ
Am J Transl Res; 2012; 4(3):247-56. PubMed ID: 22937203
[TBL] [Abstract][Full Text] [Related]
15. Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.
Wu X; Fang Z; Yang B; Zhong L; Yang Q; Zhang C; Huang S; Xiang R; Suzuki T; Li LL; Yang SY
Bioorg Med Chem Lett; 2016 May; 26(9):2284-8. PubMed ID: 27020306
[TBL] [Abstract][Full Text] [Related]
16. Identification of ryuvidine as a KDM5A inhibitor.
Mitsui E; Yoshida S; Shinoda Y; Matsumori Y; Tsujii H; Tsuchida M; Wada S; Hasegawa M; Ito A; Mino K; Onuki T; Yoshida M; Sasaki R; Mizukami T
Sci Rep; 2019 Jul; 9(1):9952. PubMed ID: 31289306
[TBL] [Abstract][Full Text] [Related]
17. Identification of potent, selective KDM5 inhibitors.
Gehling VS; Bellon SF; Harmange JC; LeBlanc Y; Poy F; Odate S; Buker S; Lan F; Arora S; Williamson KE; Sandy P; Cummings RT; Bailey CM; Bergeron L; Mao W; Gustafson A; Liu Y; VanderPorten E; Audia JE; Trojer P; Albrecht BK
Bioorg Med Chem Lett; 2016 Sep; 26(17):4350-4. PubMed ID: 27476424
[TBL] [Abstract][Full Text] [Related]
18. Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
Shokri G; Doudi S; Fathi-Roudsari M; Kouhkan F; Sanati MH
Leuk Res; 2018 May; 68():105-111. PubMed ID: 29602065
[TBL] [Abstract][Full Text] [Related]
19. Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells.
Váraljai R; Islam AB; Beshiri ML; Rehman J; Lopez-Bigas N; Benevolenskaya EV
Genes Dev; 2015 Sep; 29(17):1817-34. PubMed ID: 26314709
[TBL] [Abstract][Full Text] [Related]
20. Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors.
Jaikhan P; Buranrat B; Itoh Y; Chotitumnavee J; Kurohara T; Suzuki T
Bioorg Med Chem Lett; 2019 May; 29(10):1173-1176. PubMed ID: 30928196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
